Windtree Therapeutics, a biotechnology company registered with NASDAQ, has begun the steps required to invest in Binance Coin (BNB).
The company has announced it has signed a $500 million share credit (ELOC) and an additional $20 million share purchase agreement. The company will increase its total funding to $520 million, and will use 99% of its funds to purchase BNB.
BNB comes to Wall Street!
In an official statement, Windtree announced it had raised $520 million to buy the BNB.
Windtree will be the first Nasdaq company to gain direct exposure to BNB.
“We look forward to adding these new features that will enable future BNB purchases as part of our BNB financial strategy. With shareholder approval pending, the opportunity to raise additional funds to purchase more BNB cryptocurrencies is essential to our strategy.”
Apart from Windtree, China’s Nano Labs also announced its BNB financial strategy, making its first purchase.
*This is not investment advice.
